GlucoTrack financials
$1.74−3.33%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Fiscal year | FY25 Dec 31 | FY24 Dec 31 | FY23 Dec 31 | FY22 Dec 31 |
|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 |
| Gross profit | $0.00 | $0.00 | $0.00 | $0.00 |
| Gross margin | — | — | — | — |
| Operating income | -$16.1M | -$19.3M | -$7.1M | -$4.4M |
| Net income | -$19.4M | -$22.6M | -$7.1M | -$4.4M |
| Net margin | — | — | — | — |
| Diluted EPS | $-468.30 | $-61594.65 | $-30762.00 | $-26100.00 |
| EBITDA | -$16.0M | -$14.5M | -$7.1M | -$4.4M |
| Operating cash flow | -$15.2M | -$12.5M | -$6.6M | -$3.7M |
| Free cash flow | -$15.3M | -$12.6M | -$6.6M | -$3.7M |
| Diluted shares | 0.0M | 0.0M | 0.0M | 0.0M |
Balance sheet
| Period end | Dec 31 | Dec 31 | Dec 31 | Dec 31 |
|---|---|---|---|---|
| Cash & equivalents | $7.4M | $5.6M | $4.5M | $2.3M |
| Short-term investments | $0.00 | $0.00 | $0.00 | $0.00 |
| Total debt | $231.0K | $5.0K | $0.00 | $0.00 |
| Total assets | $7.8M | $5.9M | $4.9M | $2.4M |
| Total liabilities | $5.0M | $18.9M | $1.7M | $1.2M |
| Shareholders' equity | $2.8M | -$13.0M | $3.2M | $1.2M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology